Drug Trial Radar · NCT00459667
BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose
Last checked: Nov 20, 2026Latest source record: Apr 23, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,420
Actual
Start
May 2007
Primary completion
Mar 2008
Study completion Mar 2008
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Apr 12, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The BEYOND Follow-Up study will give patients who participated in the preceding BEYOND study the opportunity to continue treatment with the 500µg dose of interferon beta (IFNB) 1b and will further investigate the safety and tolerability profile of interferon beta 1b 500µg during longer-term treatment.
Conditions
- Multiple Sclerosis, Relapsing-Remitting
Interventions
Interferon beta-1b (Betaseron, BAY86-5046)Drug
Phase A: 250ug administrated s.c. every other day (double blind). For patients previously randomized in Bayer study 91162 to the same treatment. Phase B: All patients will receive 500µg s.c.every other day (open-label).
Interferon beta-1b (Betaseron, BAY86-5046)Drug
Phase A: 500ug administrated s.c. every other day (double blind). For patients previously randomized in Bayer study 91162 to the same treatment. Phase B: All patients will receive 500µg s.c.every other day (open-label).
Interferon beta-1b (Betaseron, BAY86-5046)Drug
Phase A: 250ug administrated s.c. every other day (open-label). For patients previously randomized in Bayer study 91162 to 20mg Copaxone® administrated s.c. once daily and patients with premature discontinuation of study medication during the study 91162. Phase B: All patients will receive 500µg s.c.every other day (open-label).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Flu-like-syndromeTime frame: 309 days
- Injection-site ReactionsTime frame: 309 days
- Liver Enzyme ElevationsTime frame: 309 days
- Hematological AbnormalitiesTime frame: 309 days
Locations
184 sites in 26 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Cullman, Alabama
Site not named
Phoenix, Arizona
Site not named
Tucson, Arizona
Site not named
Berkeley, California
Site not named
La Jolla, California
Site not named
Sacramento, California
Site not named
San Francisco, California
Site not named
Fort Collins, Colorado
Site not named
Newark, Delaware
Site not named
Washington D.C., District of Columbia
Site not named
Maitland, Florida
Site not named
Miami, Florida
Site not named
Tampa, Florida
Site not named
Tampa, Florida
Site not named
Atlanta, Georgia
Site not named
Augusta, Georgia
Site not named
Chicago, Illinois
Site not named
Fort Wayne, Indiana
Site not named
Indianapolis, Indiana
Site not named
Des Moines, Iowa
Site not named
Kansas City, Kansas
Site not named
Louisville, Kentucky
Site not named
Shreveport, Louisiana
Site not named
Detroit, Michigan
Site not named
Duluth, Minnesota
Site not named
St Louis, Missouri
Site not named
Henderson, Nevada
Site not named
Reno, Nevada
Site not named
Newark, New Jersey
Site not named
Albuquerque, New Mexico
Site not named
Mineola, New York
Site not named
Rochester, New York
Site not named
Stony Brook, New York
Site not named
Charlotte, North Carolina
Site not named
Durham, North Carolina
Site not named
Winston-Salem, North Carolina
Site not named
Cincinnati, Ohio
Site not named
Columbus, Ohio
Site not named
Tualatin, Oregon
Showing 40 of 184 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.